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ABSTRACT 
Since initial reports in the mid-1980’s there has been increasing interest in the application of 
exercise as medicine for the prevention and management of cancer. A large number of high 
quality, randomised controlled trials with cancer survivors have confirmed both aerobic and 
resistance exercise to be highly beneficial for improving body composition, quality of life, 
mental health functional capacity and reducing risk of cancer recurrence and development of 
other chronic diseases. Such benefits have ultimately been realised in reduced cancer 
mortality between 30 and 60% in large cohort retrospective studies. Treatments for prostate 
cancer are increasingly effective with quite high five and 10 year survival rates however side-
effects of endocrine treatments in particular impact on quality of life and increased co-
morbidities for the survivor. Testosterone deprivation while highly effective for controlling 
prostate cancer growth results in loss of muscle and bone and increased fat mass, increased 
incidence of metabolic syndrome, cardiovascular disease and sudden death. Exercise has 
been demonstrated to be a very effective medicine for counteracting all of these treatment 
toxicities as well as improving mental health and quality of life. Exercise has been 
demonstrated to be safe and well tolerated by cancer patients. Current recommendation is to 
complete at least 150 minutes of aerobic exercise and two or more sessions of resistance 
training per week. More specific exercise prescription is required to address particular 
treatment toxicities such as bone loss or obesity. This paper is a review of key research from 
our group into exercise medicine for prostate cancer. 
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BACKGROUND 
The earliest publication espousing the benefits of physical exercise for cancer patients 
was published by Winningham et al in 1986 in The Physician and Sports Medicine[25]. To 
quote this landmark paper “clinical observations indicate that exercise is promising restorative 
technique for cancer patients but it is a fairly new concept”. Up until this time and in fact for 
the next fifteen years or so clinicians advised cancer patients to rest and avoid activity so that 
they could better tolerate the rigors of undergoing treatment[21]. However, we now have 20 
years of research demonstrating that exercise plays a pivotal role in cancer prevention and 
management[21]. In 2005 we published a review of all exercise intervention studies in cancer 
patients up until June 2004[5]. At this time there were 26 trials with the majority of studies in 
breast cancer and utilising cardiovascular or aerobic exercise as the modality. Despite the 
fact that many of these studies implemented exercise of interventions of relatively short 
duration, sub optimal exercise selection, and relatively low intensities on the threshold for 
driving training adaptation, the benefits were quite considerable and consistent. There were 
no reported adverse events directly attributable to the exercise interventions. The major 
benefits reported were reduced fatigue, improved muscle function and physical performance, 
increased aerobic capacity, enhanced body composition and improve quality of life[5].  
 Worldwide, prostate cancer is the most common cancer in men (apart from non-
melanoma skin cancers) and the second most common cause of cancer death in men[23]. In 
Australia incidence of prostate cancer is on the increase in part because of the ageing 
demographic of the world population but also because of the introduction of the prostate 
specific antigen (PSA) test providing more frequent and earlier detection[14]. Although still 
somewhat speculative the reduction in habitual physical activity in men may also be 
contributing to increased incidence of prostate cancer[4]. Fortunately, mortality rates for 
prostate cancer are actually decreasing due to early detection and improve treatments[14]. 
   
The common treatments for prostate cancer include active surveillance (non-treatment), 
surgical removal of the prostate, radiation therapy by either external beam or brachytherapy, 
androgen deprivation therapy (ADT), and chemotherapy for metastatic disease and for 
patients that no longer respond to ADT[17].  
 Androgen deprivation is achieved through either or both elimination of testosterone 
production to administration of luteinising hormone releasing hormone antagonists (LHRHa) 
or by drugs which block the androgen receptors preventing testosterone from signalling to the 
cells. ADT is being increasingly used in the management of prostate cancer and while highly 
effective for slowing prostate cancer growth does result in a range of toxicities which impact 
negatively on the man and to varying degrees[3]. 
 We have previously reported[8] clinically significant decreases upper limb, lower limb, 
trunk and whole-body lean mass 5.6%, 3.7%, 1.4% and 2.4% respectively, while fat mass  
increased by 20.7%, 18.7%, 12.0% and 13.8% over the course of 36 weeks of ADT. Further, 
hip, spine, whole-body and upper limb bone mineral density (BMD) decreased by 1.9%, 3.3%, 
1.6% and 1.3, but not lower limb BMD during this period. In addition, physical activity levels 
decreased and levels of fatigue increased. . We have also recently reported no recovery to 
pre-treatment levels of lean and fat mass after 2 years follow-up with this cohort. Patients who 
failed to recover testosterone by 2 years post-treatment experienced significant further 
increases in fat mass compared with those who recovered eugonadal levels of 
testosterone[24]. In a subsequent cross-sectional study[12] comparing men on long-term ADT 
with matched controls without prostate cancer we reported that men on ADT had significantly 
reduced muscle strength for the upper- and lower-body and impaired functional performance 
compared to controls. As expected, ADT patients had significantly lower whole-body and hip 
BMD and higher per cent of body fat than controls and tended to have lower whole-body lean 
mass (-2.3 kg). Men undertaking ADT were consistently impaired across a broad range of 
   
physical and functional musculoskeletal performance assessments compared with their age-
matched normal controls.  
 These ADT toxicities create a “perfect storm” for falls, fracture, and the poor prognosis 
resulting from such sequelae in these men as they are predominantly of old age. ADT 
compromises balance and motor control both centrally through deprivation of testosterone to 
the brain and reduced ability of the motor system to respond effectively to a slip or trip. 
Muscle size, strength and power are reduced reducing the ability to recover from loss of 
balance. Prevalence of osteopenia and osteoporosis increase with the number of years on 
ADT such that by 10 years 100% of patients will have lower than normal BMD[18]. The 
combination of low bone density, compromised balance and ability to functionally respond 
causes increased risk of fracture of 50% or more [1].   
 The other array of ADT toxicities encompass metabolic syndrome, type II diabetes and 
the increased risk of cardiovascular disease[3]. For example it has been reported[15] that 
ADT is associated with an increased risk of diabetes (44%), coronary heart disease (16%), 
myocardial infarction (11%) and sudden death (16%) causing patients and clinicians to 
question the efficacy of ADT and possibly declining treatment. This is not without justification 
as the majority of men with prostate cancer will die of diseases other than their primary 
malignancy[3]. These treatment toxicities are of considerable concern and lead our team to 
embark on a series of studies to evaluate the efficacy of physical exercise to prevent or 
reverse such side-effects.  
 Our first study[7] involved 11 men receiving ADT for their prostate cancer. All 
participants completed a 20 week resistance training program consisting of two sessions per 
week of 12 exercises in the intensity range of 6 to 12 repetitions maximum (RM). This 
corresponds to a weight that can only be lifted 6 to 12 times. Muscle strength (chest press, 
40%; seated row, 42%; leg press, 96%) and muscle endurance (chest press, 115%; leg 
   
press, 167%) increased significantly after training. We also reported significant improvement 
in the 6-m usual walk (14.1%), 6-m backwards walk (22.3%), chair rise (26.8%), stair climbing 
(10.4%), 400-m walk (7.4%), and balance (7.8%). Muscle thickness increased by 15.7% at 
the quadriceps site. Whole-body lean mass was preserved with no change in fat mass. There 
were no significant changes in PSA, testosterone, GH, cortisol, or haemoglobin. We 
concluded that progressive resistance exercise has beneficial effects on muscle strength, 
functional performance and balance in older men receiving androgen deprivation for prostate 
cancer and should be considered to preserve body composition and reduce treatment side 
effects. This was an important early study of resistance training in this population because we 
demonstrated first that men without testosterone could respond to an appropriate exercise 
program and second the 20-week resistance training intervention period did not compromise 
therapy intent, that is there was no rise in PSA or testosterone. In a follow-up study, we 
reported that testosterone remains suppressed even immediately following an acute bout of 
high intensity resistance exercise[6]. 
 The next study[10] was a randomized controlled trial with 57 patients with prostate 
cancer undergoing AST (commenced > 2 months prior) randomly assigned to a program of 
resistance and aerobic exercise (n = 29) or usual care (n = 28) for 12 weeks. Patients 
undergoing exercise showed an increase in lean mass compared with usual care (0.8kg) and 
similarly better muscle strength (leg press 31kg) and 6-meter walk time (0.31s). Exercise also 
improved several aspects of quality of life including general health and reduced fatigue and 
decreased levels of C-reactive protein. There were no adverse events during the testing or 
exercise intervention program. Our conclusion was that relatively brief exposure to exercise 
significantly improved muscle mass, strength, physical function, and balance in hypogonadal 
men compared with normal care. The exercise regimen was well tolerated and could be 
   
recommended for patients undergoing ADT as an effective countermeasure to these common 
treatment-related adverse effects. 
 It was perplexing that a 12-week exercise intervention resulted in no significant 
reduction in body fat. To investigate this further we separated and compared those patients 
who were acutely (< 6months) or chronically (> 6months) experiencing ADT[11]. Patients on 
acute androgen deprivation showed an increase in total body fat compared to those on 
chronic ADT (0.9 kg). Each group experienced increased appendicular skeletal muscle (about 
0.5 kg). Triglycerides decreased in the chronic group and increased in the acute group. 
Change in triglycerides was associated with the change in total body fat (r = 0.411). There 
were no differences between the groups in PSA, testosterone, glucose, insulin, total 
cholesterol, low and high density lipoprotein, cholesterol, C-reactive protein, homocysteine or 
quality of life. The two groups showed similar improvement in muscle strength and function, 
and cardiovascular fitness as a result of the exercise intervention. We concluded that apart 
from differences in body fat and triglycerides the beneficial effects of exercise are similar in 
patients on acute or chronic androgen suppression therapy.  
 It was time to embark on a much longer duration clinical trial of exercise, in particular to 
address bone outcomes, which require a minimum of six months intervention to realize any 
benefit. This study[19] was 12 months in duration with the specific purpose of examining the 
effects of long term exercise on reversing musculoskeletal-related side effects, and 
cardiovascular and diabetes risk factors in men receiving androgen deprivation for their 
prostate cancer. Specifically, we aimed to investigate the effects of a 12-month exercise 
program designed to load the musculoskeletal system and reduce cardiovascular and 
diabetes disease progression on the following primary endpoints: 1) bone mineral density; 2) 
cardiorespiratory function and maximal oxygen capacity; 3) body composition (lean mass and 
fat mass); 4) blood pressure and cardiovascular function; 5) lipids and glycaemic control; and 
   
6) quality of life and psychological distress. We implemented a multi-site, randomized 
controlled trial of 195 men (65 subjects per arm) undergoing treatment for prostate cancer 
involving ADT. Participants were randomized to (1) resistance/impact loading exercise, (2) 
resistance/cardiovascular exercise groups and (3) usual care/delayed exercise. Participants 
then completed progressive training for 12 months. The impact exercise was particularly 
unique as previous research had demonstrated skipping, bounding and depth jumping 
exercises were effective for reversing bone loss in menopausal women[2]. An early 
finding[20] was that usual care resulted in a 3.2% loss of lumbar BMD and rather surprisingly 
the group completing a combination of resistance and aerobic exercise also lost 2.6%. Both of 
these changes were significant. The third group which completed a combination of resistance 
training and the impact loading protocol exhibited no significant change in bone mineral 
density over the same time period. Clearly different modes of exercise effect different aspects 
of ADT toxicity and exercise description must be highly specific to address the individual 
problems faced by these patients. Another example of exercise specificity in this patient 
population is that we are currently exploring the feasibility of a modular exercise program for 
prostate cancer patients with bone metastases[9]. 
 In 2009 our team published the Australian position stand on optimising cancer 
outcomes through exercise[13]. We reported that participating in exercise has also been 
associated with benefits during and following treatment for cancer, including improvements in 
psychosocial and physical outcomes, as well as better compliance with treatment regimens, 
reduced impact of disease symptoms and treatment-related side-effects, and survival benefits 
for particular cancers. The general exercise prescription for people undertaking or having 
completed cancer treatment was moderate intensity, regular frequency (3-5 times/week) for at 
least 20 min per session, involving aerobic, resistance or mixed exercise types.  In 2010 the 
American College of Sports Medicine convened a roundtable of experts to formulate the 
   
exercise guidelines for cancer survivors[22]. This extensive review determined that there was 
overwhelming data from RCTs that exercise for prostate cancer survivors was safe, increased 
aerobic fitness and muscle strength, and reduced fatigue. There was also evidence of 
improved body composition, quality of life and physical function. 
 While we have made the argument that exercise prescription must be specific to 
address the problems facing the patient (e.g. impact loading prescription for those with bone 
loss) the general recommendation is as follows[13]. Prostate cancer survivors should aim to 
accumulate at least 150 minutes per week of moderate aerobic exercise (between 6 to 8 on a 
10 point perceived exertion scale); and equally important two or more sessions per week of 
resistance training involving three or more sets of 6 to 8 exercises at an intensity of 6 to 10 
RM. 
 The ultimate question is whether physical exercise can actually improve survival after 
prostate cancer diagnosis. The most significant paper today has demonstrated a 49% lower 
risk of all-cause mortality and a 61% lower risk of prostate cancer death in a follow-up of 2705 
men diagnosed with non-metastatic disease[16]. Certainly it is critical to ‘‘avoid inactivity’’ 
even during difficult treatments.  
 
CONCLUSIONS 
There is overwhelming evidence that appropriate exercise is safe and well tolerated by 
prostate cancer survivors and will result in improved aerobic fitness and muscle strength as 
well as reduced fatigue. While further RCTs are required current evidence suggests that 
exercise will also enhance quality of life and physical function as well as maintain or improve 
healthy body composition. The large study by Kenfield et al.[16] has demonstrated that even 
a modest amount of vigorous exercise will result in 49% lower risk of all-cause mortality and 
61% lower risk of prostate cancer death. However the benefits of physical activity is highly 
   
specific to the exercise mode and dosage prescribed and it appears that more sophisticated 
exercise programming is required in particular to address bone and fat mass outcomes. 
 
COMPETING INTERESTS 
No competing interests. 
 
AUTHORS' CONTRIBUTIONS 
RUN and DAG researched and wrote the paper. Both authors contributed to and approved 
the final manuscript. 
   
REFERENCES 
1. Ahlborg HG, Nguyen ND, Center JR, Eisman JA, Nguyen TV (2008) Incidence and risk factors for 
low trauma fractures in men with prostate cancer. Bone 43 (3):556-560 
2. Cheng S, Sipila S, Taaffe DR, Puolakka J, Suominen H (2002) Change in bone mass distribution 
induced by hormone replacement therapy and high-impact physical exercise in post-menopausal 
women. Bone 31 (1):126-135 
3. Collins L, Basaria S (2012) Adverse effects of androgen deprivation therapy in men with prostate 
cancer: a focus on metabolic and cardiovascular complications. Asian J Androl 14 (2):222-225. 
doi:10.1038/aja.2011.109 
4. Friedenreich CM, Neilson HK, Lynch BM (2010) State of the epidemiological evidence on physical 
activity and cancer prevention. European Journal of Cancer 46 (14):2593-2604. 
doi:10.1016/j.ejca.2010.07.028 
5. Galvão DA, Newton RU (2005) Review of exercise intervention studies in cancer patients. Journal 
of Clinical Oncology 23 (4):899-909 
6. Galvao DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K, Yamaya K, McGuigan MR, 
Kristjanson LJ, Newton RU (2008) Endocrine and immune responses to resistance training in prostate 
cancer patients. Prostate Cancer and Prostatic Diseases 11 (2):160-165. doi:10.1038/sj.pcan.4500991 
7. Galvão DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, 
Newton RU (2006) Resistance training and reduction of treatment side effects in prostate cancer 
patients. Medicine and Science in Sports and Exercise 38 (12):2045-2052 
8. Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R (2008) 
Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate 
cancer. BJU International 102 (1):44-47. doi:10.1111/j.1464-410X.2008.07539.x 
9. Galvao DA, Taaffe DR, Cormie P, Spry N, Chambers SK, Peddle-McIntyre C, Baker M, Denham J, 
Joseph D, Groom G, Newton RU (2011) Efficacy and safety of a modular multi-modal exercise 
program in prostate cancer patients with bone metastases: a randomized controlled trial. BMC Cancer 
11:517. doi:10.1186/1471-2407-11-517 
10. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic 
exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate 
cancer without bone metastases: a randomized controlled trial. Journal of Clinical Oncolology 28 
(2):340-347. doi:JCO.2009.23.2488 [pii] 
10.1200/JCO.2009.23.2488 
11. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2011) Acute versus chronic exposure to 
androgen suppression for prostate cancer: impact on the exercise response. Journal of Urology 186 
(4):1291-1297. doi:10.1016/j.juro.2011.05.055 
12. Galvão DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU (2009) Reduced muscle strength 
and functional performance in men with prostate cancer undergoing androgen suppression: a 
comprehensive cross-sectional investigation. Prostate Cancer And Prostatic Diseases 12 (2):198-203 
13. Hayes SC, Spence RR, Galvao DA, Newton RU (2009) Australian Association for Exercise and 
Sport Science position stand: optimising cancer outcomes through exercise. Journal Of Science And 
Medicine In Sport / Sports Medicine Australia 12 (4):428-434. doi:10.1016/j.jsams.2009.03.002 
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics, 2008. CA 
Cancer J Clin 58 (2):71-96 
15. Keating NL, O'Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen 
deprivation therapy for prostate cancer. Journal Of Clinical Oncology: Official Journal Of The 
American Society Of Clinical Oncology 24 (27):4448-4456 
16. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM (2011) Physical activity and survival after 
prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29 (6):726-732. 
   
doi:10.1200/JCO.2010.31.5226 
17. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR (2008) Management 
of complications of prostate cancer treatment. CA: a cancer journal for clinicians 58 (4):196-213. 
doi:10.3322/CA.2008.0002 
18. Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo 
G, Reventos J (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in 
patients with prostate cancer. Urology 69 (3):500-504 
19. Newton RU, Taaffe DR, Spry N, Gardiner RA, Levin G, Wall B, Joseph D, Chambers SK, Galvao 
DA (2009) A phase III clinical trial of exercise modalities on treatment side-effects in men receiving 
therapy for prostate cancer. BMC Cancer 9:210. doi:10.1186/1471-2407-9-210 
20. Newton RU, Taaffe DR, Spry N, Joseph D, Cormie P, Gardiner R, Galvão DA (2011) High impact 
exercise preserves bone in men receiving ADT for prostate cancer. Paper presented at the 12th 
Australasian Prostate Cancer Conference., Melbourne, Australia, 3-5 August 2011 
21. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin 
ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL (2010) American 
College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports 
Exerc 42 (7):1409-1426. doi:10.1249/MSS.0b013e3181e0c112 
22. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin 
ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL (2010) American 
College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Medicine and 
Science in Sports and Exercise 42 (7):1409-1426. doi:10.1249/MSS.0b013e3181e0c112 
23. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, 
Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E 
(2012) Cancer treatment and survivorship statistics, 2012. CA: a cancer journal for clinicians 62 
(4):220-241. doi:10.3322/caac.21149 
24. Spry NA, Taaffe DR, England PJ, Judge JS, Stephens DA, Peddle-McIntyre C, Baker MK, Newton 
RU, Galvao DA (2012) Long-term effects of intermittent androgen suppression therapy on lean and fat 
mass: a 33-month prospective study. Prostate Cancer And Prostatic Diseases. 
doi:10.1038/pcan.2012.33 
25. Winningham ML, MacVicar MG, Burke CA (1986) Exercise for cancer patients: guidelines and 
precautions. The Physician and SportsMedicine 14 (10):125-134 
 
 
